

Instructions to Authors 2013

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios
 International Institute of Anticancer Research (IIAR)
 Editorial Office of ANTICANCER RESEARCH,
 IN VIVO, CANCER GENOMICS and PROTEOMICS.
 1st km Kapandritiou-Kalamou Road
 P.O. Box 22, GR-19014 Kapandriti, Attiki
 GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study. M. SALGADO, M. REBOREDO, J. C. MENDEZ, G. QUINTERO, M. L. PELLÓN, C. ROMERO, M. JORGE, A. F. MONTES, M. VALLADARES-AYERBES, M. RAMOS, S. VARELA, M. Á. ALONSO (<i>Ourense; A Coruña; Ferrol; Vigo, Spain</i>)	4089
Urinary Neopterin Concentration and Toxicity of Radiotherapy in Patients with Head and Neck Carcinoma During External Beam Radiation. P. HOLEČKOVÁ, L. KRČMOVÁ, J. LÉTAL, A. SVOBODNÍK, H. KALÁBOVÁ, M. KAŠPAROVÁ, J. PLÍŠEK, M. PÁLA, P. VÍTEK, D. SOLICHOVÁ, M. ZEŽULOVÁ, H. ŠTUDENTOVÁ, M. DOLEŽEL, B. MELICHAR (<i>Prague; Hradec Králové; Brno; Olomouc; Czech Republic</i>).....	4097
Aberrant Expression of CXCR4 and β -Catenin in Pancreatic Cancer. Z. WANG, Q. MA, P. LI, H. SHA, X. LI, J. XU (<i>Xi'an, P.R. China</i>)	4103
Anal Carcinoma: Surgery Does Not Influence Prognosis When Performed Prior to Concurrent Radiochemotherapy. H. BADA KHSHI, V. BUDACH, P. WUST, R. GRAF (<i>Berlin, Germany</i>)	4111
Image-guided Radiotherapy with Implanted Markers and Kilovoltage Imaging and 6-dimensional Position Corrections for Intrafractional Motion of the Prostate. H. BADA KHSHI, P. WUST, V. BUDACH, R. GRAF (<i>Berlin, Germany</i>)	4117
Prognostic Factors of Metastatic or Recurrent Esophageal Squamous Cell Carcinoma in Patients Receiving Three-drug Combination Chemotherapy. W. -W. CHEN, C. -C. LIN, T. -C. HUANG, A. -L. CHENG, K. -H. YEH, C. -H. HSU (<i>Taipei; Yunlin, Taiwan, R.O.C</i>)	4123
Predictive Factors for Recurrence and Survival in Hepatocellular Carcinoma in South Korea. C. H. JUN, D. W. SIM, S. H. KIM, H. J. HONG, M. W. CHUNG, E. MYOUNG, H. R. KOH, S. B. CHO, H. S. KIM, S. K. CHOI, J. S. REW (<i>Gwangju; Mokpo, Republic of Korea</i>)	4129
Errata	4135

Influence of Age on Short-term Complications after Intraoperative Radiotherapy in Women After Breast-conserving Surgery. B. TUSCHY, S. BERLIT, S. ROMERO, E. SPERK, F. WENZ, S. KEHL, M. SÜTTERLIN (<i>Mannheim, Germany</i>)	3995
Pancreatic Neuroendocrine Tumor with Ectopic Adrenocorticotropin Production: A Case Report and Review of Literature. F. B. PATEL, S. KHAGI, K. P. DALY, R. M. LECHAN, V. UMMARITCHOT, M. W. SAIF (<i>Boston, MA, U.S.A.</i>).....	4001
E6/E7 mRNA Expression of High-risk HPV Types in 849 Greek Women. E. ARGYRI, E. TSIMPLAKI, D. DASKALOPOULOU, D. J. STRAVOPODIS, O. KOUIKOGLOU, E. TERZAKIS, E. PANOTOPOULOU (<i>Athens, Greece</i>)	4007
Low-dose Fotemustine as Second-line Chemotherapy for Recurrent Glioblastoma Multiforme. F. DE FELICE, N. BULZONETTI, D. MUSIO, A. D'ELIA, M. SALVATI, V. TOMBOLINI (<i>Rome, Italy</i>)	4013
Water Swallow Screening Test for Patients After Surgery for Head and Neck Cancer: Early Identification of Dysphagia, Aspiration and Limitations of Oral Intake. C. HEY, B. P. LANGE, S. EBERLE, Y. ZARETSKY, R. SADER, T. STÖVER, J. WAGENBLAST (<i>Frankfurt/Main; Göttingen, Germany</i>)	4017
Clinical Influence of Endoscopic Resection on Subsequent Laparoscopic Gastrectomy for Gastric Cancer. S. KOMATSU, D. ICHIKAWA, T. KUBOTA, K. OKAMOTO, A. SHIOZAKI, H. FUJIWARA, H. KONISHI, R. MORIMURA, Y. MURAYAMA, Y. KURIU, H. IKOMA, M. NAKANISHI, C. SAKAKURA, T. OCHIAI, E. OTSUJI (<i>Kyoto, Japan</i>)	4023
Feasibility Study of Oxaliplatin with Oral S-1 or Capecitabine as First-line Therapy for Patients with Metastases from Colorectal Cancer. K. WATANABE, H. KAWAHARA, H. ENOMOTO, Y. TOYAMA, T. AKIBA, K. YANAGA (<i>Chiba; Tokyo, Japan</i>)	4029
Effect of Thrombosis-related Gene Polymorphisms upon Oral Cancer: A Regression Analysis. A. VYLLIOTIS, C. YAPIJAKIS, E. NKENKE, T. NISYRIOS, D. AVGOUSTIDIS, M. ADAMOPOULOU, V. RAGOS, S. VASSILIOU, N. KORONELLOS, E. VAIRAKTARIS (<i>Athens; Ioannina, Greece; Nuernberg, Germany</i>)	4033
Negative Impact of Fresh-frozen Plasma Transfusion on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. H. SHIBA, T. MISAWA, Y. FUJIWARA, Y. FUTAGAWA, K. FURUKAWA, K. HARUKI, T. IIDA, R. IWASE, K. YANAGA (<i>Tokyo, Japan</i>)	4041
Genetic Profile and Determinants of Homocysteine Levels in Kazakhstan Patients with Breast Cancer. A. AKILZHANOVA, Z. NURKINA, K. MOMYNALIEV, E. RAMANCULOV, Z. ZHUMADILOV, T. RAKHYPBKOV, N. HAYASHIDA, M. NAKASHIMA, N. TAKAMURA (<i>Nagasaki, Japan; Astana; Semey, Kazakhstan</i>).....	4049
Bevacizumab as Front-line Treatment of Brain Metastases from Solid Tumors: A Case Series. F. ZUSTOVICH, A. FERRO, G. LOMBARDI, V. ZAGONEL, P. FIDUCCIA, P. FARINA (<i>Padua, Italy</i>)	4061
Effects of Ataxia Telangiectasia Mutated (<i>ATM</i>) Genotypes and Smoking Habits on Lung Cancer Risk in Taiwan. T. -C. HSIA, C. -W. TSAI, S. -J. LIANG, W. -S. CHANG, L. -Y. LIN, W. -C. CHEN, C. -Y. TU, C. -H. TSAI, D. -T. BAU (<i>Taichung, Taiwan, R.O.C.</i>).....	4067
Phosphorylated S6 Kinase-1: A Breast Cancer Marker Predicting Resistance to Neoadjuvant Chemotherapy. E. -K. KIM, J. H. KIM, H. -A. KIM, H. SEOL, M. -K. SEONG, J. -Y. LEE, J. BYEON, Y. J. SOHN, J. S. KOH, I. -C. PARK, W. C. NOH (<i>Seoul, Korea</i>)	4073
Patient Outcome After Complete Surgery for Retroperitoneal Sarcoma. C. R. ROSSI, A. VAROTTO, S. PASQUALI, L. G. CAMPANA, S. MOCELLIN, A. SOMMARIVA, M. C. MONTESCO, M. RASTRELLI, A. VECCHIATO, P. PILATI, D. NITTI (<i>Padova, Italy</i>)	4081

Stereotactic Radiosurgery Plays a Critical Role in Enhancing Long-term Survival in a Patient with Pancreatic Cancer Metastatic to the Brain. P. RAJAPPA, K. MARGETIS, G. WERNICKE, P. GINTER, W. COPE, D. L. SHERR, E. LAVI, R. L. FINE, T. H. SCHWARTZ, H. BRUCKNER, S. C. PANNULLO (<i>New York, NY, U.S.A.</i>)	3899
Circulating Tumor Cell (CTC) Count and Epithelial Growth Factor Receptor Expression on CTCs as Biomarkers for Cetuximab Efficacy in Advanced Colorectal Cancer. Y. KUBOKI, S. MATSUSAKA, S. MINOWA, H. SHIBATA, M. SUENAGA, E. SHINOZAKI, N. MIZUNUMA, M. UENO, T. YAMAGUCHI, K. HATAKE (<i>Tokyo, Japan</i>).....	3905
A Rare Occurrence of Biphasic Pulmonary Blastoma in an Elderly Male. A. SHARMA, K. O’GORMAN, C. AMAN, D. RASSL, W. MOHAMID, A. POLYCHRONIS (<i>Northwood; Cambridge; Stevenage, U.K.</i>)	3911
Consideration of Primary Diseases and Concomitant Therapies. A. T. ASSAF, R. SMEETS, B. RIECKE, E. WEISE, A. GRÖBE, M. BLESSMANN, T. STEINER, J. WIKNER, R. E. FRIEDRICH, M. HEILAND, F. HOELZLE, F. GERHARDS (<i>Hamburg; Aachen, Germany</i>)	3917
Prediction of Nodal Metastasis and Prognosis of Breast Cancer by ANN-based Assessment of Tumour Size and p53, Ki-67 and Steroid Receptor Expression. S. MOJARAD, B. VENTURINI, P. FULGENZI, R. PAPALETTO, M. BRISIGOTTI, F. MONTI, D. CANUTI, A. RAVAIOLI, L. WOO, S. DLAY, G. V. SHERBET (<i>Newcastle upon Tyne, U.K.; Rimini, Italy; Huntington Beach, CA, U.S.A.</i>)	3925
The Surgeon as the Most Important Factor in Lymph Node Harvest During Axillary Clearance. D. N. NAUMANN, M. SINTLER (<i>Birmingham, U.K.</i>)	3935
Impact of Chemotherapy with S-1 and Oxaliplatin (SOX) in Combination with Molecular-targeting Agents on Colorectal Liver Metastases. K. WATANABE, H. KAWAHARA, H. ENOMOTO, Y. TOYAMA, T. AKIBA, K. YANAGA (<i>Chiba; Tokyo, Japan</i>)	3941
A High Serum Uric Acid Level Is Associated with Poor Prognosis in Patients with Acute Myeloid Leukemia. T. YAMAUCHI, E. NEGORO, S. LEE, M. TAKAI, Y. MATSUDA, K. TAKAGI, S. KISHI, K. TAI, N. HOSONO, T. TASAKI, S. IKEGAYA, K. INAI, A. YOSHIDA, Y. URASAKI, H. IWASAKI, T. UEDA (<i>Eiheiji, Japan</i>)	3947
Prognostic Value of Nuclear Translocation of Aryl Hydrocarbon Receptor for Non-small Cell Lung Cancer. J. -M. SU, P. LIN, H. CHANG (<i>Taichung; Zhunan, Taiwan, R.O.C.</i>).....	3953
Comparisons of Late Vaginal Mucosal Reactions Between Interstitial and Conventional Intracavitary Brachytherapy in Patients with Gynecological Cancer: Speculation on the Relation Between Pallor Reaction and Stenosis. K. YOSHIDA, H. YAMAZAKI, S. NAKAMURA, K. MASUI, T. KOTSUMA, S. J. BAEK, H. AKIYAMA, E. TANAKA, Y. YOSHIOKA (<i>Takatsuki; Kyoto; Osaka; Suita, Japan</i>)	3963
Podoplanin and VEGF-C Immunoexpression in Oral Squamous Cell Carcinomas: Prognostic Significance. A. D. S. ALMEIDA, D. T. OLIVEIRA, M. C. PEREIRA, S. E. S. FAUSTINO, S. NONOGAKI, A. L. CARVALHO, L. P. KOWALSKI (<i>Bauru; Divinópolis; São Paulo; Barretos, Brazil</i>)	3969
Microsatellite Instability Analysis for the Screening of Synchronous Endometrial and Ovarian Cancer in Lynch Syndrome. A. -S. BATS, H. ROUSSEL, C. NARJOZ, M. -A. LE FRERE-BELDA, F. CHAMMING’S, H. BLONS, P. LAURENT-PUIG, F. LECURU (<i>Paris, France</i>)	3977
<i>TXNDC5</i> Gene Polymorphism Contributes to Increased Risk of Hepatocellular Carcinoma in the Korean Male Population. M. -S. PARK, S. K. KIM, H. P. SHIN, S. -M. LEE, J. -H. CHUNG (<i>Seoul, Republic of Korea</i>)..	3983
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Sarcomatosis: Long-term Outcome from a Single Institution Experience. A. SOMMARIVA, S. PASQUALI, P. DEL FIORE, M. C. MONTESCO, P. L. PILATI, M. RASTRELLI, J. NIBA, D. NITTI, C. R. ROSSI (<i>Padova, Italy</i>).....	3989

Zoledronic Acid-induced Cytotoxicity Through Endoplasmic Reticulum Stress Triggered REDD1-mTOR Pathway in Breast Cancer Cells. Y.-C. LAN, C. -L. CHANG, M. -T. SUNG, P. -H. YIN, C. -C. HSU, K. -C. WANG, H. -C. LEE, L. -M. TSENG, C. -W. CHI (<i>Taipei, Taiwan, R.O.C.</i>).....	3807
Vascular Endothelial Growth Inhibitor (VEGI) Is an Independent Indicator for Invasion in Human Pituitary Adenomas. W. JIA, A. J. SANDER, G. JIA, M. NI, X. LIU, R. LU, W. G. JIANG (<i>Beijing, P. R. China; Cardiff, U.K.</i>).....	3815
<i>Clinical Studies</i>	
Combination Metronomic Oral Topotecan and Pazopanib: A Pharmacokinetic Study in Patients with Gynecological Cancer. D. C. TURNER, T. D. TILLMANN, K. E. HARSTEAD, S. L. THROM, C. F. STEWART (<i>Memphis, TN, U.S.A.</i>).....	3823
Docetaxel in the Treatment of Non-small Cell Lung Cancer (NSCLC) – An Observational Study Focusing on Symptom Improvement. A. PIRCHER, I. K. WASLE, M. MIAN, G. GAMERITH, E. ULSPERGER, M. STUDNICKA, A. MOHN-STAUDNER, W. HILBE, M. FIEGL (<i>Innsbruck; Vienna; Salzburg, Austria</i>)	3831
Efficacy of Combined Androgen Blockade with Zoledronic Acid Treatment in Prostate Cancer with Bone Metastasis: The ZABTON-PC (Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer) Study. S. UENO, A. MIZOKAMI, T. FUKAGAI, N. FUJIMOTO, H. OH-OKA, Y. KONDO, G. ARAI, H. IDE, S. HORIE, O. UEKI, K. KAWAGUCHI, M. SHIMAMURA, M. ORITO, T. ISHIDA, D. IKEDA, M. NAMIKI (<i>Kanazawa; Tokyo; Fukuoka; Kobe; Koshigaya; Nanao; Takaoka, Japan</i>)	3837
Pharmacokinetic Assessment of Irinotecan, SN-38, and SN-38-Glucuronide: A Substudy of the FIRIS Study. T. SATOH, H. YASUI, K. MURO, Y. KOMATSU, S. SAMESHIMA, K. YAMAGUCHI, K. SUGIHARA (<i>Suita; Shizuoka; Nagoya; Sapporo; Saitama; Tokyo, Japan</i>)	3845
Immunological Response after <i>WT1</i> mRNA-loaded Dendritic Cell Immunotherapy in Ovarian Carcinoma and Carcinosarcoma. A. COOSEMANS, A. VANDERSTRAETEN, S. TUYAERTS, T. VERSCHUERE, P. MOERMAN, Z. BERNEMAN, I. VERGOTE, F. AMANT, S. W. VAN GOOL (<i>Leuven; Antwerp, Belgium</i>)	3855
Vitamin D Favorably Alters the Cancer Promoting Prostaglandin Cascade. W. QIN, C. SMITH, M. JENSEN, M. F. HOLICK, E. R. SAUTER (<i>Tyler, TX; Fargo, ND; Boston, MA, U.S.A.</i>).....	3861
Morbid Obesity Does Not Disadvantage Patients with <i>In Situ</i> or Early-stage Carcinoma Undergoing Breast-conserving Surgery. F. AMPIL, G. CALDITO, B. LI, S. DEVARAKONDA, G. BURTON, R. H. KIM, Q. CHU (<i>Shreveport, LA, U.S.A.</i>)	3867
<i>In Vitro</i> Demonstration of Synergy/Additivity Between ¹⁸⁸ Rhenium and Sorafenib on Hepatoma Lines: Preliminary Results. M. PRACHT, J. EDELINE, N. LEPAREUR, L. LENOIR, V. ARDISSON, B. CLEMENT, J. -L. RAOUL, O. AUDRAIN, E. BOUCHER, E. GARIN (<i>Rennes; Marseille, France</i>)	3871
Brentuximab Vedotin: First-line Agent for Advanced Hodgkin Lymphoma. H. CAO, K. YAMAMOTO, L. -X. YANG, R. WEBER (<i>San Francisco, CA, U.S.A.</i>)	3879
Number of Involved Extracranial Organs Predicts Survival in Patients with Brain Metastasis from Small Cell Lung Cancer. L. GERDAN, B. ŠEGEDIN, T. VENINGA, S. E. SCHILD, D. RADES (<i>Lübeck, Germany; Ljubljana, Slovenia; Tilburg, the Netherlands; Scottsdale, AZ, U.S.A.</i>).....	3887
Definition of p53 Overexpression and its Association with the Clinicopathological Features in Luminal/HER2-negative Breast Cancer. S. KIKUCHI, R. NISHIMURA, T. OSAKO, Y. OKUMURA, Y. NISHIYAMA, Y. TOYOZUMI, N. ARIMA (<i>Kumamoto, Japan</i>)	3891

<i>HER2/neu</i> Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy. M. BRUNELLI, E. MANFRIN, E. BRIA, F. MASSARI, G. TORTORA, E. BRUNELLO, L. CARBOGNIN, A. NOTTEGAR, J. FURLANETTO, A. MOLINO, E. FIORIO, M. CHILOSI, B. JASANI, M. VERGINE, L. MARCOLINI, D. FILIPPINI, A. SCARPA, G. MARTIGNONI, F. BONETTI (<i>Verona, Italy; Cardiff; Brighton, U.K.</i>)	3705
Differential Expression of p-mTOR in Cutaneous Basal and Squamous Cell Carcinomas Likely Explains their Different Response to mTOR Inhibitors in Organ-transplant Recipients. G. KARAYANNOPOULOU, S. EUVRARD, J. KANITAKIS (<i>Thessaloniki, Greece; Lyon, France</i>)	3711
Tumor-stromal Interactions with Direct Cell Contacts Enhance Motility of Non-small Cell Lung Cancer Cells Through the Hedgehog Signaling Pathway. C. CHOE, Y. -S. SHIN, S. -H. KIM, M. -J. JEON, S. -J. CHOI, J. LEE, J. KIM (<i>Seoul, Republic of Korea</i>)	3715
The Diagnostic Value of Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Measurement in the Sera of Patients with Endometrial Cancer. K. ORYWAL, W. JELSKI, M. ZDRODOWSKI, M. SZMITKOWSKI (<i>Bialystok, Poland</i>).....	3725
Utility of ATP7B in Prediction of Response to Platinum-based Chemotherapy in Urothelial Bladder Cancer. S. C. SCHMID, T. SCHUSTER, T. HORN, J. GSCHWEND, U. TREIBER, G. WEIRICH (<i>Munich, Germany</i>)	3731
Antitumorigenic Effect of Dietary Natural Compounds via Lipid Metabolism Modulation in <i>Apc^{Min/+}</i> Mice. M. NOTARNICOLA, V. TUTINO, A. TAFARO, F. AMATULLI, M. G. CARUSO (<i>Bari, Italy</i>)	3739
Expression of α B-Crystallin and Vascular Endothelial Growth Factor in Conjunctival Squamous Cell Carcinoma. Z. DONG, S. KASE, R. ANDO, J. FUKUHARA, S. KINOSHITA, Y. DONG, S. TAKASHINA, A. KANDA, M. NODA, K. NODA, S. ISHIDA (<i>Sapporo, Japan</i>)	3745
Combination of the EGFR Tyrosine Kinase Inhibitor AG1478 and 5-FU: No Synergistic Effect on EGFR Phosphorylation, Cell Proliferation and Apoptosis Induction. V. YAGUBLU, Z. AHMADOVA, Y. HAJIYEVA, M. HAFNER, M. KEESE (<i>Mannheim; Frankfurt, Germany</i>)	3753
PTK7 Expression in Triple-negative Breast Cancer. B. ATASEVEN, R. ANGERER, R. KATES, A. GUNESCH, P. KNYAZEV, B. HÖGEL, C. BECKER, W. EIERMANN, N. HARBECK (<i>Munich; Essen; Martinsried, Germany</i>)	3759
Frequent Promoter Methylation of <i>CDHI</i> in Non-neoplastic Mucosa of Sporadic Diffuse Gastric Cancer. K. H. LEE, D. HWANG, K. Y. KANG, S. LEE, D. Y. KIM, Y. E. JOO, J. H. LEE (<i>Gwangju; Namwon, Republic of Korea</i>)	3765
<i>ESR1</i> Gene Amplification in Endometrial Carcinomas: A Clinicopathological Analysis. M. T. RAHMAN, K. NAKAYAMA, M. RAHMAN, M. ISHIKAWA, H. KATAGIRI, A. KATAGIRI, T. ISHIBASHI, E. SATO, K. IIDA, N. ISHIKAWA, N. NAKAYAMA, K. MIYAZAKI (<i>Izumo, Japan</i>)	3775
Macrophage Apolipoprotein E and Proliferation of MCF-7 Breast Cancer Cells: Role of LXR. A. EL ROZ, J. -M. BARD, S. VALIN, J. -M. HUVELIN, H. NAZIH (<i>Nantes, France</i>).....	3783
Lewis Lung Carcinoma Progression Is Facilitated by TIG-3 Fibroblast Cells. Y. YAMAUCHI, Y. IZUMI, K. ASAKURA, K. KAWAI, M. WAKUI, M. OHMURA, M. SUEMATSU, H. NOMORI (<i>Tokyo; Kanagawa, Japan</i>)	3791
Multiple Anticancer Effects of Damsin and Coronopilin Isolated from <i>Ambrosia arborescens</i> on Cell Cultures. R. VILLAGOMEZ, G. C. RODRIGO, I. G. COLLADO, M. A. CALZADO, E. MUÑOZ, B. ÅKESSON, O. STERNER, G. R. ALMANZA, R. -D. DUAN (<i>La Paz, Bolivia; Lund, Sweden; Cadiz; Córdoba, Spain</i>)	3799

Efficacy of Liposomal Curcumin in a Human Pancreatic Tumor Xenograft Model: Inhibition of Tumor Growth and Angiogenesis. A. P. RANJAN, A. MUKERJEE, L. HELSON, R. GUPTA, J. K. VISHWANATHA (<i>Fort Worth, TX; Quakertown, PA, U.S.A.</i>)	3603
Stable Knockdown of <i>hCGβ</i> mRNA Expression in Bladder Cancer Cells Results in Significant Growth Inhibition. B. BURCZYNSKA, M. J. BOOTH, R. K. ILES, A. SHAH, A. SHILED, S. A. BUTLER (<i>London; Crieff, Scotland, U.K.; Poznan, Poland</i>)	3611
Antitumor Activity of Elacytarabine Combined with Bevacizumab, Cetuximab and Trastuzumab in Human NSCLC Xenografts. S. BRUHEIM, M. L. SANDVOLD, G. M. MÆLANDSMO, Ø. FODSTAD (<i>Oslo, Norway</i>)	3615
High Lung-metastatic Variant of Human Osteosarcoma Cells, Selected by Passage of Lung Metastasis in Nude Mice, Is Associated with Increased Expression of $\alpha_v\beta_3$ Integrin. Y. TOME, H. KIMURA, H. MAEHARA, N. SUGIMOTO, M. BOUVET, H. TSUCHIYA, F. KANAYA, R. M. HOFFMAN (<i>San Diego, CA, U.S.A.; Okinawa; Kanazawa, Japan</i>)	3623
Effect of Liposomal Curcumin on Red Blood Cells <i>In Vitro</i> . A. STORKA, B. VCELAR, U. KLICKOVIC, G. GOUYA, S. WEISSHAAR, S. ASCHAUER, L. HELSON, M. WOLZT (<i>Vienna; Klosterneuburg, Austria; Quakertown, PA, U.S.A.</i>)	3629
Prediction of Immune Surveillance Responsive Metastatic Prostate Cancer in Pelvic Lymph Node and Emergence of Surveillance Unresponsive/Resistant Metastatic Cells. A. A. SINHA, E. T. FERNANDES, S. L. EWING, M. J. WILSON (<i>Minneapolis, MN, U.S.A.</i>)	3635
Enhanced Redox Factor 1 (REF1)-modulated p53 Stabilization and JNK1 Dissociation in Response to Selenomethionine. H. J. JUNG, H. L. KIM, Y. R. SEO (<i>Bronx, NY, U.S.A.; Seoul, Republic of Korea</i>) ...	3645
The Neutrophil Elastase Inhibitor Sivelestat Suppresses Accelerated Gastrointestinal Tumor Growth via Peritonitis After Cecal Ligation and Puncture. K. KUMAGAI, Y. SAIKAWA, H. TAKEUCHI, K. SUDA, K. FUKUDA, R. NAKAMURA, T. TAKAHASHI, H. KAWAKUBO, N. WADA, T. MIYASHO, Y. KITAGAWA (<i>Tokyo; Hokkaido, Japan</i>)	3653
Malignant Progressive Tumor Cell Clone Exhibits Significant Up-regulation of Cofilin-2 and 27-kDa Modified Form of Cofilin-1 Compared to Regressive Clone. Y. KURAMITSU, Y. WANG, F. OKADA, B. BARON, K. TOKUDA, T. KITAGAWA, J. AKADA, K. NAKAMURA (<i>Ube; Yonago, Japan</i>)	3661
Effects of Dietary Calcium on <i>Helicobacter pylori</i> -induced Gastritis in Mongolian Gerbils. M. IIMURO, S. NAKAMURA, T. ARAKAWA, K. WAKABAYASHI, M. MUTOH (<i>Hyogo; Osaka; Shizuoka; Tokyo, Japan</i>)	3667
Vagus Nerve Regulates Breast Cancer Metastasis to the Adrenal Gland. N. ERIN, G. A. BARKAN, G. A. CLAWSON (<i>Antalya, Turkey; Maywood, IL; Hershey, PA, U.S.A.</i>)	3675
Association of Slow Acetylation Profile of <i>NAT2</i> with Breast and Gastric Cancer Risk in Brazil. M. R. FERNANDES, D. C. DE CARVALHO, Â. K. C. R. DOS SANTOS, S. E. B. DOS SANTOS, P. P. DE ASSUMPÇÃO, R. M. R. BURBANO, N. P. C. DOS SANTOS (<i>Belém, Brazil</i>)	3683
Fluoxetine-induced Apoptosis in Hepatocellular Carcinoma Cells. A -R. MUN, S. -J. LEE, G. -B. KIM, H. -S. KANG, J. -S. KIM, S. -J. KIM (<i>Jeonju, Republic of Korea</i>)	3691
Tropomyosin-related Kinase B Inhibitor Has Potential for Tumor Regression and Relapse Prevention in Pulmonary Large Cell Neuroendocrine Carcinoma. S. ODATE, H. ONISHI, K. NAKAMURA, M. KOJIMA, A. UCHIYAMA, M. KATO, M. KATANO (<i>Fukuoka, Japan</i>)	3699